FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289779551> ?p ?o ?g. }

• W4289779551 endingPage "e2224478" @default.
• W4289779551 startingPage "e2224478" @default.
• W4289779551 abstract "<h3>Importance</h3> The 2017 international PACIFIC trial established a role for immunotherapy after chemoradiation for unresectable stage III non–small cell lung cancer (NSCLC). However, in the US, patients with NSCLC commonly differ from clinical trial populations in terms of age, health, access to care, and treatment course, which may all factor into the efficacy of immunotherapy. <h3>Objective</h3> To determine the outcomes of immunotherapy use in unresectable stage III NSCLC in the general US population. <h3>Design, Setting, and Participants</h3> This cohort study analyzed the National Cancer Database for patients diagnosed with clinical stage III NSCLC between 2015 and 2017 with follow-up through the end of 2018 who were treated with chemotherapy and radiation. Data were analyzed January 2022. <h3>Main Outcomes and Measures</h3> Mortality hazard in a multivariable Cox proportional hazards model and survival among a propensity-matched sample treated with chemotherapy and radiation, with and without immunotherapy. <h3>Results</h3> A total of 23 811 patients with clinical stage III NSCLC with median (IQR) age 66 (59-72) years met inclusion criteria (10 454 [43.9%] women; 564 [2.4%] Asian, 2930 [12.3%] Black, 20 077 [84.3%] White patients), including 209 (16.1%) patients with multiple comorbidities and 1297 (5.4%) immunotherapy recipients. Immunotherapy after chemotherapy and radiation was associated with reduced mortality (hazard ratio [HR], 0.74; 95% CI, 0.67-0.82;<i>P</i> < .001). Among a propensity-matched sample, immunotherapy was associated with superior 3-year survival (52% [1297 patients at 0 months, 56 patients at 36 months] vs 44% [2594 patients at 0 months, 173 patients at 36 months];<i>P</i> < .001). The treatment of 833 patients who received immunotherapy (64.2%) differed from the PACIFIC trial protocol, including 221 patients (17.0%) who received radiation doses outside of the protocol range and 731 patients (56.4%) who started immunotherapy more than 6 weeks after radiation was completed. The survival advantage of immunotherapy persisted when initiated up to 12 weeks after radiation was completed (HR, 0.75; 95% CI, 0.61-0.92). Among patients who received radiation outside the PACIFIC protocol range, the survival advantage of immunotherapy was not significant (HR, 0.87; 95% CI, 0.69-1.01). <h3>Conclusions and Relevance</h3> In this cohort study, immunotherapy after chemotherapy and radiation for stage III NSCLC was associated with a survival advantage in the general US population despite two-thirds of patients treated differently than the PACIFIC protocol. The findings suggest there may be flexibility in the timing of immunotherapy initiation after radiation; further study is warranted to clarify the clinical benefits of immunotherapy." @default.
• W4289779551 created "2022-08-04" @default.
• W4289779551 creator A5000482706 @default.
• W4289779551 creator A5006849637 @default.
• W4289779551 creator A5021339490 @default.
• W4289779551 creator A5028192791 @default.
• W4289779551 creator A5039567045 @default.
• W4289779551 creator A5039998258 @default.
• W4289779551 creator A5042314992 @default.
• W4289779551 creator A5055418535 @default.
• W4289779551 creator A5063268337 @default.
• W4289779551 creator A5068529118 @default.
• W4289779551 creator A5079485527 @default.
• W4289779551 creator A5085410813 @default.
• W4289779551 date "2022-08-04" @default.
• W4289779551 modified "2023-09-26" @default.
• W4289779551 title "Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer" @default.
• W4289779551 cites W1994791246 @default.
• W4289779551 cites W2017103032 @default.
• W4289779551 cites W2065974896 @default.
• W4289779551 cites W2118502261 @default.
• W4289779551 cites W2152939220 @default.
• W4289779551 cites W2214259081 @default.
• W4289779551 cites W2592783575 @default.
• W4289779551 cites W2753065806 @default.
• W4289779551 cites W2893824814 @default.
• W4289779551 cites W2898452483 @default.
• W4289779551 cites W2942703462 @default.
• W4289779551 cites W2995072671 @default.
• W4289779551 cites W3006075183 @default.
• W4289779551 cites W3015050105 @default.
• W4289779551 cites W3021472140 @default.
• W4289779551 cites W3033724663 @default.
• W4289779551 cites W3092724916 @default.
• W4289779551 cites W3107733830 @default.
• W4289779551 cites W3108819942 @default.
• W4289779551 cites W3111048504 @default.
• W4289779551 cites W3123920206 @default.
• W4289779551 cites W3150122335 @default.
• W4289779551 cites W3166324988 @default.
• W4289779551 cites W3172131160 @default.
• W4289779551 cites W3174198239 @default.
• W4289779551 cites W3192669545 @default.
• W4289779551 cites W3194813465 @default.
• W4289779551 cites W3205880571 @default.
• W4289779551 cites W3212033356 @default.
• W4289779551 cites W4210477674 @default.
• W4289779551 cites W4249214711 @default.
• W4289779551 cites W4256026521 @default.
• W4289779551 cites W4362198532 @default.
• W4289779551 doi "https://doi.org/10.1001/jamanetworkopen.2022.24478" @default.
• W4289779551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35925606" @default.
• W4289779551 hasPublicationYear "2022" @default.
• W4289779551 type Work @default.
• W4289779551 citedByCount "2" @default.
• W4289779551 countsByYear W42897795512023 @default.
• W4289779551 crossrefType "journal-article" @default.
• W4289779551 hasAuthorship W4289779551A5000482706 @default.
• W4289779551 hasAuthorship W4289779551A5006849637 @default.
• W4289779551 hasAuthorship W4289779551A5021339490 @default.
• W4289779551 hasAuthorship W4289779551A5028192791 @default.
• W4289779551 hasAuthorship W4289779551A5039567045 @default.
• W4289779551 hasAuthorship W4289779551A5039998258 @default.
• W4289779551 hasAuthorship W4289779551A5042314992 @default.
• W4289779551 hasAuthorship W4289779551A5055418535 @default.
• W4289779551 hasAuthorship W4289779551A5063268337 @default.
• W4289779551 hasAuthorship W4289779551A5068529118 @default.
• W4289779551 hasAuthorship W4289779551A5079485527 @default.
• W4289779551 hasAuthorship W4289779551A5085410813 @default.
• W4289779551 hasBestOaLocation W42897795511 @default.
• W4289779551 hasConcept C121608353 @default.
• W4289779551 hasConcept C126322002 @default.
• W4289779551 hasConcept C143998085 @default.
• W4289779551 hasConcept C146357865 @default.
• W4289779551 hasConcept C151730666 @default.
• W4289779551 hasConcept C207103383 @default.
• W4289779551 hasConcept C2776256026 @default.
• W4289779551 hasConcept C2776694085 @default.
• W4289779551 hasConcept C2777701055 @default.
• W4289779551 hasConcept C2908647359 @default.
• W4289779551 hasConcept C44249647 @default.
• W4289779551 hasConcept C50382708 @default.
• W4289779551 hasConcept C509974204 @default.
• W4289779551 hasConcept C535046627 @default.
• W4289779551 hasConcept C71924100 @default.
• W4289779551 hasConcept C86803240 @default.
• W4289779551 hasConcept C99454951 @default.
• W4289779551 hasConceptScore W4289779551C121608353 @default.
• W4289779551 hasConceptScore W4289779551C126322002 @default.
• W4289779551 hasConceptScore W4289779551C143998085 @default.
• W4289779551 hasConceptScore W4289779551C146357865 @default.
• W4289779551 hasConceptScore W4289779551C151730666 @default.
• W4289779551 hasConceptScore W4289779551C207103383 @default.
• W4289779551 hasConceptScore W4289779551C2776256026 @default.
• W4289779551 hasConceptScore W4289779551C2776694085 @default.
• W4289779551 hasConceptScore W4289779551C2777701055 @default.
• W4289779551 hasConceptScore W4289779551C2908647359 @default.
• W4289779551 hasConceptScore W4289779551C44249647 @default.

• next